The expression levels of CBX7 are reduced in some tumors, and it is correlated with the clinicopathological parameters of several tumors, including breast cancer, bladder cancer, colon cancer, and glioma [4,5,6,7]. This evidence concerns the gene CBX7 and central nervous system cancer.